Diabetes mellitus

United States $15.9 Bn Diabetes Devices Market - Growth, Trends, and Forecast 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 30, 2019
Health, Diabetes, Medicine, Clinical medicine, Endocrine system, Diabetes, Medical monitoring, RTT, Blood tests, Blood glucose monitoring, Diabetes mellitus, Continuous glucose monitor, Physical security information management, Glucose meter

The "United States Diabetes Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Diabetes Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The USA diabetes devices market has been estimated to be valued at USD 15.9 billion in 2019, registering a CAGR of 9.17% during the forecast period (2019-2024).
  • The main types of diabetes care devices include glucose monitoring devices and management devices.
  • The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices.

Northeast Georgia Medical Center to Implement eGlycemic Management System® from Glytec

Retrieved on: 
Tuesday, July 30, 2019
Hardware, Data management, Surgery, Technology, Science, Nursing, Medical Supplies, FDA, Diabetes, Other Health, Pharmaceutical, Practice Management, Nanotechnology, Other Science, Managed care, Medical devices, Research, General Health, Hospitals, Genetics, Fitness & Nutrition, Clinical trials, Cardiology, Biotechnology, Health, Software, Endocrine system, Organ systems, Medicine, Eli Lilly and Company, Diabetes, RTT, Insulin, Glycemic, Diabetes mellitus, Diabetes management, Bruce Bode

Our organization is steadfastly committed to clinical excellence in diabetes care and glycemic management, says Dr. Suhel Patel, Medical Director and Chair, Inpatient Medicine, Northeast Georgia Physicians Group.

Key Points: 
  • Our organization is steadfastly committed to clinical excellence in diabetes care and glycemic management, says Dr. Suhel Patel, Medical Director and Chair, Inpatient Medicine, Northeast Georgia Physicians Group.
  • View the full release here: https://www.businesswire.com/news/home/20190730005103/en/
    Northeast Georgia Medical Center, in partnership with Glytec, is taking advanced measures to optimize glycemic management and ensure the safety and efficacy of insulin therapy.
  • Challenges surrounding insulin therapy are well documented in the medical literature, and as a high-alert medication , considerable safety precautions are imperative, explains Cindy Danner, Associate Chief Nursing Officer, Northeast Georgia Medical Center Gainesville Campus.
  • Members of Glytecs Clinical Services and Quality Initiatives teams will work with Northeast Georgia Medical Center to tailor glycemic management workflows and order sets.

Canadians Who Plan For 'lows', Stay On Top Of Their Diabetes!

Retrieved on: 
Tuesday, July 30, 2019
RTT, Organ systems, Diabetes, Endocrine diseases, Endocrine system, Hypoglycemia, Idiopathic postprandial syndrome, Diabetes mellitus type 1, Glucagon, Diabetes mellitus, Diabetic hypoglycemia

That said, when an individual care plan is in place, everyone around you knows what to do, if you go 'low'.

Key Points: 
  • That said, when an individual care plan is in place, everyone around you knows what to do, if you go 'low'.
  • The recent survey showed that hypoglycemia is top of mind, with most respondents 'always' or 'sometimes' worrying about severe episodes.
  • The #whatsyourrescueplan campaign includes a new website resource where anyone can download a severe hypoglycemia rescue plan template, customize the plan and discuss it with their health care team.
  • an EpiPen) for a severe allergic reaction, glucagon, a medication for people with diabetes is a key part of any rescue plan.

France Diabetes Market Report 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 29, 2019
Diabetes, Pharmaceutical, Health, RTT, Organ systems, Business, Marketing strategy, Diabetes mellitus, Medicine, Clinical medicine

The "France Diabetes Market Report: 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "France Diabetes Market Report: 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • This new report France Diabetes Market Report: 2019-2024 provides an analytical and statistical insight into the France diabetes market.
  • The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the France diabetes market.
  • This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the France diabetes market in any form.

Hillrom Introduces Next-Generation Breakthrough Technology In Fight Against Diabetic Retinopathy

Retrieved on: 
Monday, July 29, 2019
Organ systems, RTT, Ophthalmology, Vision, Diabetes, Retinopathy, Diabetic retinopathy, Visual impairment, Diabetes mellitus, Retina

Diabetic retinopathy is the leading cause of blindness in working-age adults1.

Key Points: 
  • Diabetic retinopathy is the leading cause of blindness in working-age adults1.
  • "The new RetinaVue 700 Imager represents an exciting growth opportunity and an outstanding demonstration of our promise of Advancing Connected Care."
  • A new study3 demonstrates that image quality from the RetinaVue 700 Imager is as good as a leading large, automated non-mydriatic tabletop camera.
  • Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by advancing connected care.

Cintas Corporation Joins the American Diabetes Association® to Drive Awareness of Diabetes in the Workplace

Retrieved on: 
Tuesday, July 30, 2019
Education, Medical Supplies, Diabetes, Public policy, Government, Retail, Other Professional Services, Human resources, Training, General Health, Professional services, Office Products, Law enforcement, Emergency services, Health, Small business, Diabetes, RTT, Organ systems, American Diabetes Association, Medicine, Diabetes mellitus, Cintas, Clinical medicine, Education, Medical Supplies, Diabetes, Public policy, Government, Retail, Other Professional Services, Human resources, Training, General Health, Professional services, Office Products, Law enforcement, Emergency services, Health, Small business, Organ systems, RTT, Medicine, American Diabetes Association, Diabetes mellitus, Diabetes, Cintas, Education, Medical Supplies, Diabetes, Public policy, Government, Retail, Other Professional Services, Human resources, Training, General Health, Professional services, Office Products, Law enforcement, Emergency services, Health, Small business, Diabetes, RTT, Organ systems, American Diabetes Association, Medicine, Diabetes mellitus, Cintas, Clinical medicine, Cintas Corporation, the American Diabetes Association

Cintas Corporation (NASDAQ: CTAS), a leading provider of workplace first aid, safety supplies and training services, is collaborating with the American Diabetes Association (ADA) to drive awareness about diabetes in the workplace.

Key Points: 
  • Cintas Corporation (NASDAQ: CTAS), a leading provider of workplace first aid, safety supplies and training services, is collaborating with the American Diabetes Association (ADA) to drive awareness about diabetes in the workplace.
  • Cintas customers can now select products to include in their cabinets from those recognized by the ADA, which will help drive awareness of diabetes.
  • The American Diabetes Association (ADA) is the nations leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.
  • Join the fight with us on Facebook ( American Diabetes Association ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn ).

Insulet to Debut New Educational Self-Advocacy Tool at 20th Annual Children with Diabetes Friends for Life Conference

Retrieved on: 
Wednesday, July 17, 2019
Health, Medical devices, Diabetes, General Health, Biotechnology, Diabetes, RTT, Organ systems, Medicine, Diabetes mellitus, Chronic condition

The site will be launched in connection with the Companys participation at the 20th Annual Children with Diabetes Friends for Life conference taking place in Orlando, Florida, July 17-19, 2019.

Key Points: 
  • The site will be launched in connection with the Companys participation at the 20th Annual Children with Diabetes Friends for Life conference taking place in Orlando, Florida, July 17-19, 2019.
  • I have been living with type 1 diabetes, a silent, chronic disease for 47 years, said Bob Parant, diabetes advocate and person with type 1 diabetes.
  • Your story and voice can and must be heard to create positive change and shape the future for people with diabetes.
  • These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet.

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA

Retrieved on: 
Thursday, July 25, 2019
RTT, Organ systems, Endocrine system, Medicine, Eli Lilly and Company, Diabetes, Glucagon, Diabetes mellitus type 1, Hypoglycemia, Insulin, Diabetes mellitus, Diabetic hypoglycemia

BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind.

Key Points: 
  • BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind.
  • BAQSIMI is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI.
  • Acquired by Lilly from Locemia Solutions in 2015, BAQSIMI is a new formulation of rescue glucagon that builds upon Lilly's diabetes heritage.
  • Glucagon nasal powder: a promising alternative to glucagon for injection in youth with type 1 diabetes.

FDA approves first treatment for severe hypoglycemia that can be administered without an injection

Retrieved on: 
Wednesday, July 24, 2019
Endocrine system, Organ systems, Endocrine diseases, Diabetes, RTT, Eli Lilly and Company, Medical emergencies, Hypoglycemia, Insulin, Diabetes mellitus, Idiopathic postprandial syndrome, Diabetic hypoglycemia

SILVER SPRING, Md., July 24, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.

Key Points: 
  • SILVER SPRING, Md., July 24, 2019 /PRNewswire/ --The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.
  • Typically, severe hypoglycemia occurs in people with diabetes who are using insulin treatment.
  • Baqsimi is approved to treat severe hypoglycemia in patients with diabetes ages four and older.
  • "People who are living with diabetes are at risk of their blood sugar levels falling below the normal range.

Russia Diabetes Market Report 2019

Retrieved on: 
Tuesday, July 23, 2019
RTT, Organ systems, Diabetes mellitus, Marketing strategy, Medicine, Clinical medicine

DUBLIN, July 23, 2019 /PRNewswire/ -- The "Russia Diabetes Market Report: 2019 - 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 23, 2019 /PRNewswire/ -- The "Russia Diabetes Market Report: 2019 - 2024" report has been added to ResearchAndMarkets.com's offering.
  • Russia Diabetes Market Report: 2019 - 2024 provides an analytical and statistical insight into the Russia diabetes market.
  • The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Russia diabetes market.
  • This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Russia diabetes market in any form.